NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv- 09413 […]

NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ:CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Cargo and certain of its officers and/or

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capri Holdings Limited("Capri" or the "Company") (NYSE:CPRI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Capri and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Joint Stock Company Kaspi.kz ("Kaspi.kz" or the "Company") (NASDAQ:KSPI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against DMC Global Inc. ("DMC Global," "DMC," or the "Company") (NASDAQ:BOOM) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 25-cv-XXXXX,

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against ASP Isotopes Inc. ("ASPI" or the "Company") (NASDAQ:ASPI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Block, Inc. ("Block" or the "Company") (NYSE: SQ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ:PCRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether AstraZeneca and certain of its officers and/or directors have

https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock ofKyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. So what: If you purchased Kyverna common stock you may